Securitisation

The ABX index: A pricing conundrum

The liquidity crisis in the ABS market has led to investors using the ABX index as a valuation tool for individual securities - something the index was never designed for. Ben Logan explains the ramifications of this valuation practice

The squeeze is on - The clampdown on CDO ratings

The rating agencies have faced a barrage of criticism over their role in last year's subprime meltdown. This year they have been focusing on ensuring that a repeat of the ABS problems do not occur in other segments of the structured credit market. But…

Column: Nigel Sillis

The structured products that were once viewed as the F1 cars of the financial world - complex, efficient, high-performance - are now looking more like exhibits from Wacky Races

Legal Spotlight

ABS investors may shudder at the mention of the word 'subprime', but that shouldn't deter issuers from using securitisation to raise capital. In our special extended feature, Neal Handa and Bruce Bloomingdale look at how the credit crisis has affected…

Valuing CDOs of ABSs

Charles Smithson and Neil Pearson discuss the valuation of collateralised debt obligations (CDOs), with a close look at CDOs of subprime residential mortage-backed securities

Credit risk: learning from the crunch

New business opportunities bring new risks. The market innovations that helped precipitate the credit crisis demonstrate that a complex new approach to risk management is required - and that means thinking beyond models based on derivatives and Basel II,…

Monolines - the nuclear option

XL Capital Assurance and Financial Guaranty Insurance Company (FGIC) face legal action by three banks after cancelling insurance contracts they had written on asset-backed securities transactions.

A clearer picture

Fraud has gone to the top of the postmortem on the US subprime debacle. To detect and prevent it, more information at the loan level is needed, and the standardisation of data would also help investors in mortgage-backed securities make better decisions,…

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here